drugset / Trial / NCT04664738

PEP on a Skin Graft Donor Site Wound

NCT04664738

Phase 1 Unknown 8 enrolled Rion Inc. ProPharma Group · collab
Non-randomizedSequentialSingle-blindTreatment

Summary

The purpose of this study is to determine the safety of a biological therapeutic PEP in participants who have skin graft donor site wounds.

Timeline

Start
2021-03-16
Primary completion
2023-08-09
Completion
2024-02-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Fibrinogen Concentrate Human Protein / enzyme biologic
Subject PEP Other / unclassified 10 %
Subject PEP Other / unclassified 20 %

Indications

No indication recorded.